PMID- 10940688
OWN - NLM
STAT- MEDLINE
DCOM- 20000921
LR  - 20171101
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 62 Suppl 1
DP  - 2000
TI  - Natural history of neuroendocrine enteropancreatic tumors.
PG  - 51-8
AB  - Neuroendocrine enteropancreatic tumors (NEEPTs) include tumors developing from 
      the pancreatic islets and the duodenal loop, and those developing from gut 
      serotonin-secreting cells (mid-gut carcinoids). When functioning, they are rare 
      tumors with frequently inconsistant clinical and biological characteristics. 
      Provocative dynamic tests are very useful. Their natural history, with the 
      exception of insulinomas and mid-gut carcinoids, is still incompletely known due 
      to their rarity, relatively recent description, slow evolution and the absence of 
      definitive reliable markers for prognosis. The following factors affect the 
      natural history of NEEPTs. (1) Inclusion or not within the spectrum of multiple 
      endocrine neoplasia type-1 (MEN1), such an integration often dramatically 
      modifies the management strategy. In patients with MEN1, NEEPTs are often 
      multiple, diffusely spread in the duodenopancreatic area and of small size. 
      Definite cure by surgery is then very scarce. Mid-gut carcinoid tumors are the 
      most protean NEEPTs. In contrast to appendiceal carcinoids, usually with a benign 
      course, mid-gut carcinoids have a more malignant course and are very common 
      indeed: local transmural invasion, early metastasis to lymph nodes and/or liver, 
      and symptoms from hormone oversecretion. Carcinoid syndrome is usually well 
      controlled by long-acting somatostatin analogs. (2) Disease spreading, i.e. liver 
      and bone metastases, are the major causes of death in patients with NEEPTs. Liver 
      metastases (LMs) are synchronous in about 75% of the patients with LMs but may 
      develop during follow-up (about 25% of the patients with LMs were without LMs at 
      the initial evaluation). Development of bone metastases has a very poor prognosis 
      accompanying LM progression.
CI  - Copyright 2000 S. Karger AG, Basel
FAU - Mignon, M
AU  - Mignon M
AD  - Department of Hepato-Gastroenterology and Inserm U.410, Paris, France. 
      michael.mignon@bch.ap-hop-paris.fr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
SB  - IM
MH  - Carcinoid Tumor/pathology
MH  - Digestive System Neoplasms/epidemiology/*pathology
MH  - Duodenal Neoplasms/pathology
MH  - Humans
MH  - Neuroendocrine Tumors/epidemiology/*pathology
MH  - Pancreatic Neoplasms/pathology
RF  - 30
EDAT- 2000/08/15 11:00
MHDA- 2000/09/23 11:01
CRDT- 2000/08/15 11:00
PHST- 2000/08/15 11:00 [pubmed]
PHST- 2000/09/23 11:01 [medline]
PHST- 2000/08/15 11:00 [entrez]
AID - 51856 [pii]
AID - 10.1159/000051856 [doi]
PST - ppublish
SO  - Digestion. 2000;62 Suppl 1:51-8. doi: 10.1159/000051856.